Prosecution Insights
Last updated: May 29, 2026

Examiner: YU, DELPHINUS DOU YI

Tech Center 1600 • Art Units: 1636 1645 1651

This examiner grants 0% of resolved cases

Performance Statistics

0.0%
Allow Rate
-60.0% vs TC avg
19
Total Applications
+0.0%
Interview Lift
150
Avg Prosecution Days
Based on 1 resolved cases, 2023–2026

Rejection Statute Breakdown

0%
§101 Eligibility
3.6%
§102 Novelty
57.1%
§103 Obviousness
28.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18452127 HIGH-THROUGHPUT METHODS FOR ANALYZING AND AFFINITY-MATURING AN ANTIGEN-BINDING MOLECULE Non-Final OA 10x Genomics, Inc.
18249016 PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF RETINAL OR CHOROIDAL DISEASE COMPRISING PLVAP AS ACTIVE INGREDIENT Non-Final OA UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION
18254324 MEDIATORS OF GENE SILENCING Non-Final OA CANCER RESEARCH TECHNOLOGY LIMITED
18457605 GENE SILENCING THERAPY OF ACUTE RESPIRATORY DISORDER Non-Final OA Therapeutic Solutions International, Inc.
17603347 COMPOSITIONS AND METHODS FOR THE STABILIZATION OF MICRO-RNA Final Rejection GENFIT
18495687 SIRNAS AGAINST KRAS AND RAF1 Non-Final OA SIRNAOMICS, INC.
17951842 METHODS FOR PREPARING NANOPARTICLE COMPOSITIONS CONTAINING HISTIDINE-LYSINE COPOLYMERS Non-Final OA Sirnaomics, Inc.
18269479 APTAMERS AND USE OF THE APTAMERS IN THE DIAGNOSIS AND TREATMENT OF A SARS-COV-2 INFECTION Non-Final OA RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN
18184721 VIRULENCE FACTOR FSPL GENE FROM SUGARCANE POKKAH BOENG DISEASE AND USE THEREOF Non-Final OA GUANGXI UNIVERSITY
18266592 GENE TRANSCRIPTION FRAMEWORK, VECTOR SYSTEM, GENOME SEQUENCE EDITING METHOD AND APPLICATION Non-Final OA Shuanghong PENG
15734918 LABELING OF DNA Non-Final OA Bionano Genomics, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month